T1	p 34 80	with flosequinan in congestive heart failure .
T2	p 239 359	patients with moderate to severe congestive heart failure . Seventeen patients on chronic digitalis and diuretic therapy
T3	p 394 411	flosequinan ( n =
T4	p 1169 1225	patients with moderate to severe chronic heart failure .
T5	i 14 33	vasodilator therapy
T6	i 143 156	flosequinan ,
T7	i 159 212	new orally administered arterial and venous dilator ,
T8	i 394 409	flosequinan ( n
T9	i 412 428	9 ) or placebo (
T10	i 853 864	flosequinan
T11	i 1045 1064	vasodilator therapy
T12	i 1070 1081	flosequinan
T13	i 1085 1112	standard digitalis-diuretic
T14	o 476 545	symptomatology , exercise performance , and left ventricular function
T15	o 668 712	symptom scores and functional classification
T16	o 809 836	maximal exercise capacity .
T17	o 920 938	resting heart rate
T18	o 984 1018	left ventricular systolic function